Accelerated vaccine development against emerging infectious diseases

Vaccine and Immunotherapy Center, Infectious Diseases Medicine, Massachusetts General Hospital
Human Vaccines & Immunotherapeutics (Impact Factor: 2.37). 07/2012; 8(7):1010-2. DOI: 10.4161/hv.20805
Source: PubMed


Emerging and re-emerging infectious diseases represent a major challenge to vaccine development since it involves two seemingly contradictory requirements. Rapid and flexible vaccine generation while using technologies and processes that can facilitate accelerated regulatory review. Development in the "-omics" in combination with advances in vaccinology offer novel opportunities to meet these requirements. Here we describe how a consortium of five different organizations from academia and industry is addressing these challenges. This novel approach has the potential to become the new standard in vaccine development allowing timely deployment to avert potential pandemics.

Download full-text


Available from: Pierre Regent Leblanc, Sep 27, 2015
5 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Computational vaccine design, also known as computational vaccinology, encompasses epitope mapping, antigen selection and immunogen design using computational tools. The iVAX toolkit is an integrated set of tools that has been in development since 1998 by De Groot and Martin. It comprises a suite of immunoinformatics algorithms for triaging candidate antigens, selecting immunogenic and conserved T cell epitopes, eliminating regulatory T cell epitopes, and optimizing antigens for immunogenicity and protection against disease. iVAX has been applied to vaccine development programs for emerging infectious diseases, cancer antigens and biodefense targets. Several iVAX vaccine design projects have had success in pre-clinical studies in animal models and are progressing towards clinical studies. The toolkit now incorporates a range of immunoinformatics tools for infectious disease and cancer immunotherapy vaccine design. This article will provide a guide to the iVAX approach to computational vaccinology.
    Human Vaccines & Immunotherapeutics 07/2015; 11(9). DOI:10.1080/21645515.2015.1061159 · 2.37 Impact Factor